Denali Therapeutics Q3 EPS $(0.72) Beats $(0.82) Estimate, Sales $1.27M Down From $3.56M YoY
Portfolio Pulse from Benzinga Newsdesk
Denali Therapeutics reported Q3 losses of $(0.72) per share, beating the analyst consensus estimate of $(0.82) by 12.2%. This is a 14.29% increase over losses from the same period last year. However, the company's sales decreased by 64.4% YoY to $1.27 million.
November 07, 2023 | 10:06 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Denali Therapeutics reported better than expected Q3 losses but saw a significant decrease in sales YoY.
While Denali Therapeutics beat the Q3 EPS estimate, the significant decrease in sales could be a concern for investors. This mixed result may lead to neutral short-term price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100